Walvax Biotechnology 沃森生物
26 significant filings since 30 May 2026: 22 on share issue, 1 on dividend and 3 on issue review inquiry. The latest, on 24 Sep 2026: 北京市竞天公诚律师事务所关于云南沃森生物技术股份有限公司2026年度向特定对象发行股票的补充法律意见书（二）.
自 30 May 2026 起有 26 份重大公告：share issue 22 份、dividend 1 份、issue review inquiry 3 份。最新一份（24 Sep 2026）：北京市竞天公诚律师事务所关于云南沃森生物技术股份有限公司2026年度向特定对象发行股票的补充法律意见书（二）。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 0 brokers | 0 brokers |
| 7 days ago | 0 brokers | 0 brokers |
| 30 days ago | 0 brokers | 0 brokers |
| 60 days ago | 0 brokers | 0 brokers |
| 90 days ago | 0 brokers | 0 brokers |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
| Last 90 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0.